FierceBiotech· @FierceBiotech · X·· 2 小时前精选AI 评分58
AI 导读
Kyntra Bio(原FibroGen)在未达到疗效阈值后,终止了其二期前列腺癌ADC项目。这是该公司遭遇的又一次挫折。
推荐理由
该二期前列腺癌ADC项目因未达到疗效阈值被终止,读者可据此了解该管线的最新进展。
正文
Another setback for Kyntra Bio. The former FibroGen has scrapped its phase 2 prostate cancer ADC program after failing to meet an efficacy threshold. https://www.fiercebiotech.com/biotech/kyntra-axes-mid-stage-adc-adding-years-myriad-stumbles
来源:FierceBiotech · x.com